Current Report Filing (8-k)
July 27 2020 - 7:49AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: July 24, 2020
(Date
of earliest event reported)
Oragenics,
Inc.
(Exact
name of registrant as specified in its charter)
FL
|
|
001-32188
|
|
59-3410522
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
Number)
|
4902
Eisenhower Boulevard, Suite 125
Tampa,
FL
|
|
33634
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
OGEN
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01. OTHER EVENTS.
Oragenics
Inc. (the “Company”) provides an update on the recent exercise of certain outstanding warrants.
Warrant
Exercises. Of the Company’s previously reported remaining outstanding warrants to acquire 4,294,500 shares of Common
Stock at an exercise price of $1.00 per share issued in connection with its July 2018 public offering (the “2018 Warrants”),
an additional 750,000 warrants have been exercised through July 24, 2020. In addition, of the Company’s previously reported
outstanding warrants to acquire 9,583,334 shares of Common Stock at an exercise price of $0.90 per share issued in connection
with its March 2019 public offering (the “2019 Warrants”), 4,787,365 warrants have been exercised through July 24,
2020. The warrant exercises have provided aggregate gross proceeds to the Company of $5,058,628.
Additional
Consideration Payment. In connection with the Company’s previously disclosed acquisition of Noachis Terra Inc. (“NTI”)
the Company is obligated to pay additional consideration to NTI’s former stockholder determined and based upon the exercise
of the Company’s 2018 Warrants and 2019 Warrants. As a result of the exercises the Company is obligated to pay $1,199,225
of the aggregate gross proceeds the Company received to NTI’s former stockholder.
Common
Stock Outstanding. As of July 24, 2020, the Company has 60,900,168 shares of Common Stock issued and outstanding inclusive
of the aforementioned warrant exercises.
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 27th day of July, 2020.
|
ORAGENICS, INC.
(Registrant)
|
|
|
|
BY:
|
/s/
Michael Sullivan
|
|
|
Michael
Sullivan
Chief
Financial Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024